Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
August 2026—Beckman Coulter Diagnostics has launched in the U.S. its DxU 1800 system, a fully automated urinalysis solution that combines the new DxU 1800c chemistry analyzer with a DxU Iris microscopy analyzer.
August 2026—Diazyme Laboratories has acquired Carolina Liquid Chemistries Corp., an FDA-registered manufacturer and reseller of chemistry systems and reagents.
August 2026—Zepto Life Technology has introduced FungiFlex Pneumocystis jirovecii, a targeted plasma cell-free DNA liquid biopsy assay for the detection of P. jirovecii, and the FungiFlex Mold Plus panel, which combines invasive mold detection with P. jirovecii in a single plasma-based test order.
August 2026—Streck has received in vitro diagnostic clearance for three MDx-Chex controls for sepsis testing. MDx-Chex for BCY, MDx-Chex for BCP, and MDx-Chex for BCN are patient-like, ready-to-use, full-process molecular quality controls designed for verification of the Diasorin Liaison Plex yeast, Gram-positive, and Gram-negative blood culture assays, respectively. The controls are supplied in 10 single-use vial kits and feature room-temperature storage.
August 2026—Pictor Holdings debuted its next-generation high-resolution platform, the PictImager, at the Association for Diagnostics and Laboratory Medicine Annual Meeting and Clinical Lab Expo (July 26–30, Anaheim, Calif.).
August 2026—Werfen and Oxford Nanopore Technologies have entered a strategic collaboration to validate Werfen’s transplant assay portfolio, including solutions for human leukocyte antigen typing and pretransplant matching, for use on Oxford Nanopore sequencing platforms.
August 2026—Clarapath launched TrimStar Pro, an FDA-registered facing and trimming solution designed to help histology laboratories take a step toward automation.
August 2026—At the University of Pittsburgh’s Computational Pathology and AI Center of Excellence (CPACE), artificial intelligence research in disease detection begins with a practical reality: most of the data still lives on glass.
July 2026—Sysmex America has introduced the XR-Series, a hematology solution designed to help laboratories deliver fast, reliable results while maintaining efficient workflows. The next-generation XR-Series builds on the capabilities of the XN-Series, adding higher throughput, enhanced analytics, and complementary solutions that aim to streamline daily laboratory operations.
July 2026—Roche introduced the Cobas MPX-E assay, a qualitative in vitro test for the detection and discrimination of HIV 1 and 2 and hepatitis C, B, and E viruses, in countries accepting the CE mark. By identifying these pathogens simultaneously, the assay aims to help laboratories streamline their operations while enhancing the safety of blood and blood products for patients.
